| DISC DEGENERATION: THE NEED FOR NOVEL TREATMENTS
Degeneration of the intervertebral disc (IVD) is an age-related process that is characterized by a catabolic shift, leading to matrix breakdown and-ultimately-structural failure. Apparent degenerative changes first occur in the nucleus pulposus (NP) and are associated with a shift from collagen type II to more fibrotic collagen type I as well as with a reduction in proteoglycans and a consequent loss in hydration and disc height. 1 However, the annulus fibrosus (AF) also undergoes degenerative changes as evidenced by disorganization of the lamellar structure, possibly leading to structural defects, such as clefts and tears. 2 The altered biomechanical status during degeneration contributes to the development of tissue damage through the creation of areas of peak stress, exposing the disintegrated tissue to hyperphysiological loading that it cannot withstand. 3 As the IVD possesses little regenerative capacity, and healing can only take place in the outer AF where nutrient supply is greatest, degeneration gradually progresses without treatment.
Although disc degeneration is a main contributor to back pain, only a subpopulation will become symptomatic and experience so-called degenerative disc disease (DDD) that is associated with increased expression of inflammatory molecules, including interleukins IL-1β, IL-8, and IL-6 and tumor necrosis factor (TNF)-α (reviewed in References [4] [5] [6] [7] ). At the moment, patients suffering from DDD are initially treated conservatively, that is with physiotherapy and analgesic medication, but may have to undergo discectomy if symptoms do not improve. Thus, current therapies only target symptoms but not the underlying molecular processes contributing to disc degeneration and pain development. Accordingly, major effort has been made to design novel, biologically targeted treatment options over the past years, with a focus on 2 approaches:
On the one hand, regenerative therapies to counteract the degeneration process have been attempted but without compelling results thus far. The use of cellular therapies, for example, stem cell treatment, is negatively affected by the harsh microenvironment of the IVD that is characterized by high mechanical loads, inflammatory cytokines, hypoxia, low glucose levels, acidic pH, and high osmolarity. 8 The application of anabolic substances promoting the production of extracellular matrix (ECM) is hampered by the low cellularity within the IVD (4000 cells/mm 3 in the NP and 9000 cells/mm 3 in the AF) and, furthermore, by the fact that these few cells are metabolically not very active. 9, 10 The outcome of injection of classical anabolic factors such as bone morphogenetic protein (BMP)-7, transforming growth factor (TGF)-β, or growth differentiation factor (GDF)-5 is compromised even more by the short half-life of these growth factors and their rapid diffusion out of the IVD. 8 On the other hand, numerous recent research activities have focused on the means to modulate inflammation in the IVD, mostly The CRISPR/Cas9 system is composed of the bacterial endonuclease Cas9, which can be directed to any DNA sequence by singleguide RNA (sgRNA). sgRNA is a short synthetic RNA composed of a scaffold sequence necessary for Cas9-binding, that is made of crRNA, loop, and trans-activating crRNA (tracrRNA), and a user-defined, variable 17-20 nucleotide spacer that defines the genomic target to be modified. 20 The short nucleotide spacer of sgRNA is complementary to the genomic DNA target sequence in close proximity to the protospacer adjacent motif (PAM) that, in case of Cas9 obtained from
Streptococcus pyogenes, is a conserved NGG sequence. However, the PAM is not part of gRNA as it is only present downstream of the target DNA (Figure 1) . 21, 22 The recognition of the target DNA is ensured IVD phenotype and could also be applied directly in IVD cells. 42 In cartilage research, the Swarm rat chondrosarcoma (RCS) cell line is commonly used to study chondrocyte-specific phenotype due to its similarity to normal rat cartilage and ability to generate cell clones. Recently, an RCS cell line stably expressing Cas9 (RCS-Cas9) was developed and used to investigate the function of the ECM molecules aggrecan and hyaluronan. 43, 44 aggrecan knockout in RCS-Cas9 cells provided additional knowledge on the role of aggrecan in cell attachment, chondrosarcoma formation, and gene regulation, 43 while knockout of hyaluronan synthase-2 revealed the essential role of hyaluronan in the assembly of chondrocyte pericellular matrix. 44 In a chondrogenic mouse teratocarcinoma cell line (ATDC5), CRISPR/ Cas9-mediated deletion of the specific binding site of the microRNA miR-322, reduced mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1) protein levels, and provided new insights into cartilage development. where a specific antibody is fused to a dCas9 coexpressed with a gRNA. 58 In IVD research, specifically in studies focusing on IVD oxygenation, enCHiP could, for example, be used to investigate the interaction between hypoxia-responsive elements (HREs) and hypoxia- CRISPR/Cas9 represents a major asset to generate in vivo disease models, such as transgenic mice. Compared to traditional methods, this approach is faster, easier, and more cost effective, and protocols consisting of the injection of a plasmid construct containing the Cas9 and gRNA in mouse zygotes are available. 71 Another approach is to replace the nucleus of an isolated oocyte with the nucleus of a geneedited somatic cell, 72 thus rendering the use of embryonic stem cells obsolete. In addition to single points, 73 large domains can also be mutated, 74 and multiple genes can be targeted simultaneously, with an efficiency of 95% for single mutants and 80% for double mutants. 28 More recently, in vivo genome editing in specific tissue has been demonstrated by synthetic short-lived gRNA-Cas9 RNP complexes. 75 As genetics is postulated to be a main contributor to disc degeneration and DDD, 76 in vivo models expressing Cas9 specifically in the IVD or delivery of short-lived RNP specifically to the IVD will be useful to better understand the role of highlighted candidate genes in disease progression. Such genes include the vitamin D receptor, aggrecan, type IX collagen, asporin, MMP3, IL-1, and IL-6 as polymorphisms in these genes may influence IVD degeneration mechanisms. 77 In vivo inducible systems based on dCas9 have been particularly useful in phenotypic and epigenetic studies in postnatal mammals and in cancer models, allowing the study of gene-level changes. 78 Besides serving the purpose of translational medicine, animal models are also used for research in developmental biology. Notably, notochordal cells are currently of great interest in the IVD scientific community. In the field of spine and cartilage development, the zebrafish is a useful model and a powerful tool for in vivo CRISPR-based screenings. 88 CRISPR/Cas9 kinesin-I deletion in zebrafish revealed the role of this gene in cartilage remodeling and chondrocyte maintenance during craniofacial morphogenesis, 89 while CRISPR/Cas9 knockout of cavin1b in the embryonic notochord showed that caveolae, which are formed by Cavin1b, mediate the mechanoprotection of notochordal cells during development. 90 Recently, a zebrafish model of idiopathic scoliosis was created by CRISPR/Cas9 deletion of mapk7. 
| Ex vivo edited autologous IVD cells
Autologous IVD cells can be obtained from biopsies removed during surgeries. These cells are frequently affected by pre-existing degeneration and suffer from poor expansion rates in vitro. 95, 96 Nevertheless, ment. This will have profound effects on both cell therapeutics and gene therapies for IVD degeneration application. However, the field has much to learn about the delivery and safety of these systems.
Despite these challenges, CRISPR/Cas9 represents a promising new tool that has the potential to break through technological barriers that have been impeding the field's progress and therefore change our thinking and treatment of IVD degeneration, DDD, and LBP.
